We're Searching for a Way to Live Life Beyond the Mask

If you are a resident or staff member of a participating long-term care facility, you may qualify for the BLAZE-2 Study for COVID-19.

Meeting an Urgent Need with a Unique Study

Studies have shown that COVID-19 can spread rapidly in nursing homes. By October 30, 2020, at least 580,000 nursing home residents and staff members had contracted COVID-19 in the United States, accounting for over a third of the country’s COVID-19 deaths. Nursing home residents and staff members have an urgent need for COVID-19 treatments. Eli Lilly and Company, a US-based pharmaceutical company, has partnered with the National Institute of Allergy and Infectious Diseases (NIAID) on the BLAZE-2 Study to meet this need.

Long-term care facilities across the US are participating in the BLAZE-2 Study. Researchers are trying to learn if an investigational medicine, given alone or in combination with another one, could prevent COVID-19 or new infections of the virus that causes COVID-19. For each participating facility, the study begins when a resident or staff member tests positive for COVID-19, and it enrolls volunteers at the facility for less than one week. Study appointments happen at the facility for most participants. You could be one of them.

The Study at a Glance

The BLAZE-2 Study is available at up to 2000 long-term care facilities across the US. If you are a resident or staff member at a participating facility, you may have the opportunity to take part in this important research. Staff members in quarantine can arrange for study appointments to take place in their home, rather than at their facility.

Trial

Condition
COVID‑19
Potential Treatment Under Study
LY-CoV555
LY-CoV555 + LYCoV016

What's Involved?

Maximum Trial Length
3 or 6 months, depending on COVID-19 status
Appointments
At your facility

Who Qualifies?

COVID-19 Status
Negative or positive test result at start of study
Ages
18+

About the Study Drugs

The BLAZE-2 Study is testing whether an investigational medicine, given alone or in combination with another one, could prevent COVID-19. The US FDA is allowing these investigational medicines, called LY-CoV555 and LY-CoV016, to be used for research as part of the development process of new medicines. Both investigational medicines are a common type of drug that scientists make to mimic part of the body’s immune system. They are not vaccines. Study participants may receive either LY-CoV555 alone, LY-CoV555 and LY-CoV016 together, or a placebo (no active medicine).

Why Participate?

Each person and each research study are different. Every research study has risks and benefits to consider when deciding whether to participate. If you qualify, you and your loved ones are the only ones who can decide if participation is the right choice for you.

You may want to take part in this study for the following reasons:

Advance Medicine

Move COVID-19 research forward and possibly help find a treatment that may help others

Become Involved

Take an active role in your health by staying informed and exploring new potential treatment options

Access Study Drug

Possibly try an investigational medicine for COVID-19 that is currently available only for research

Interested in helping us search for a way to live life beyond the mask?